 CytoDyn Inc revealed that Brazils regulatory authority Agência Nacional de Vigilância Sanitária ANVISA has approved the start of an additional Phase 3 CD16 clinical trial of its flagship drug leronlimab to treat critically ill coronavirus COVID-19 patients. The Vancouver, Washington-based late-stage biotechnology company said the new clinical trial will focus on hospitalized COVID-19 patients in critical condition who require mechanical and invasive ventilation or Extracorporeal Membrane Oxygenation ECMO. 